Eric Lefkofsky: AstraZeneca and Merck bet on AI with Tempus in oncology

Eric Lefkofsky: AstraZeneca and Merck bet on AI with Tempus in oncology
AstraZeneca and Merck pursue AI in oncology

Two of the pharmaceutical industry's leading executives, Pascal Soriot of AstraZeneca and Rob Davis of Merck, have underscored their companies' ongoing strategic partnerships with Tempus. The collaborations focus on leveraging artificial intelligence in the field of oncology. 

Eric Lefkofsky's commentary follows the announcement of these partnerships, which aim to accelerate the integration of AI solutions for cancer diagnostics and therapies. The involvement of major pharmaceutical firms signals continued investment in digital health innovation.

Eric Lefkofsky previously introduced Preview, an AI platform that delivers pathology insights to doctors within 24 hours, aiming to speed up clinical decision-making for patient care

Tempus recently secured U.S. FDA approval for its xT CDx platform, expanding tumor-only genomic profiling access to more patients. Both developments highlight Tempus's ongoing push to integrate advanced technology into oncology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.